# High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

> **NCT06345495** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Splenomegaly
- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib
- **PROCEDURE:** Allogeneic Stem Cell Transplantation
- **DRUG:** Levetiracetam
- **DRUG:** Eltrombopag
- **DRUG:** Busulfan
- **DRUG:** Romiplostim
- **DRUG:** Fludarabine phosphate
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT06345495
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06345495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06345495, "High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06345495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*